Biofilm Formation and Antifungal Resistance in Candida Species

Biofilm Formation and Antifungal Resistance in Candida Species: A Comparative Study of Albicans and Non Albicans Strains in Hematology ICU.

1. To determine the susceptibility pattern of our local isolated Candida strains which is essential for optimal management of fungal infection.
2. Detection of biofilm formation by conventional and molecular methods
3. Comparison between C. albicans and non-albicans in the prevalence of biofilm formation and biofilm -forming genes
4. Find the association between antifungal resistance and biofilm formation in candida strains isolated from patients
5. Determination of clinical factors associated with occurrence of infections.

Study Overview

• Status: Not yet recruiting
• Conditions: Candida Infection

Detailed Description

Candida spp are the fourth cause of nosocomial blood stream infections and had a 37% mortality rate within 30-day duration. Early diagnosis of Candida invasive infections reduces the mortality rate from 40% to 15% after therapy .There are several Candida species such as Candida albicans , Candida glabrata but C. albicans remains the most frequent species isolated there is an ongoing shift from C. albicans to non-albicans. Was reported by several countries. C. albicans, C. tropicalis, C. parapsilosis,C. krusei and C. glabrata are responsible for over 90% of cases of candidal infection .Several pathogenic virulence factors are encoded by C. albicans genes and assist the fungus to invade the host tissues leading to infections as the capacity of C. albicans to change from the budding yeast form to filamentous form .Many microbes, including yeasts, form biofilms as one of the major virulence factors. Candida infections often get therapeutic failure, mostly as a result of antifungal resistance that is caused by several mechanisms including biofilm production as biofilm- producing strains show significant increased resistance to antifungal drugs and host immunity.

Candida auris is an emergent pathogen that was first described in Japan. C. auris can be challenging to identify in the laboratory using conventional. Importantly, C. auris isolates are resistant to fluconazole and frequently show multidrug resistance.C. auris has a high capacity for dissemination via contaminated surfaces or horizontal patient-to-patient transfer, which is unusual in other Candida species.

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

• Study Contact: Name: mennat-allah khaled abdelhady; Phone Number: 00201151387078; Email: roserena2@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

patients admitted to hematology intensive care

Description

Inclusion Criteria:

• Eligible participants in the study were those with invasive infection and had one or more of this criteria :

oSuppressed general body immunity.

oSuppressed local body immunity as a result of trauma or invasive procedures.

oResistant to antibiotic therapy.

oNegative samples for bacterial examination and culture.

Critical life threatening infect

Exclusion Criteria:

• Patients who received antifungal therapy within 3 days prior to sample collection.

  • Resistant to antibiotic therapy.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To asses the prevalence of candida species as a cause of infection in patient in hematology intinsive care unit	1 year
To asses the prevalence of genes responsible for biofilm formation in different candida species	1 year

Collaborators and Investigators

• Sponsor: Assiut University

Study record dates

Study Major Dates

• Study Start (Estimated): December 20, 2025
• Primary Completion (Estimated): September 20, 2026
• Study Completion (Estimated): October 12, 2026

Study Registration Dates

• First Submitted: October 2, 2025
• First Submitted That Met QC Criteria: November 17, 2025
• First Posted (Actual): November 24, 2025

Study Record Updates

• Last Update Posted (Actual): November 24, 2025
• Last Update Submitted That Met QC Criteria: November 17, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Bacterial Infections and Mycoses; Mycoses; Candidiasis
• Other Study ID Numbers: candida species identification

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No